A Breast Cancer Test That Saves Lives

The BT Test(R) - A Simple Blood Test for the Early Detection of Breast Cancer

PHOENIX, Nov. 3 /PRNewswire/ -- A healthy 44-year-old woman will celebrate
many future birthdays thanks to the efforts of Dr. Keri Sweeten and a new
blood test for breast cancer.

Dr. Sweeten, a board-certified gynecologist and Fellow of the American College
of Obstetricians and Gynecologists, recently incorporated the Provista Life
Science BT Test®, a blood test for the detection of breast cancer, into her
patient care practice. Sweeten noted a case where a 44-year-old patient called
to schedule her annual mammogram, and in advance of the mammogram Sweeten
ordered the BT Test. When her patient's BT Score® came back high, indicating
an increased likelihood of the presence of breast cancer, she changed the
order for her patient's routine screening mammogram to a diagnostic bilateral
mammogram.

A diagnostic mammogram is an enhanced radiology procedure that increases the
number and angles of breast imaging views with increased magnification of
those views. Using this procedure, the radiologist was able to locate a deep,
very small clustering of suspicious looking cells in the patient's left
breast. A biopsy was recommended, performed and the subsequent pathologist's
report came back with a confirmed diagnosis of cancer. Surgery was scheduled
two weeks later and the cancerous growth removed.

"My patient is a young woman with dense breast tissue where the sensitivity of
digital and film mammography is known to be limited, but is still considered
the standard of care. Had it not been for the BT Test, we might not have
caught her cancer," said Sweeten. "My patient's first reply to me was, 'You
saved my life.' I'm not sure much more needs to be said."

The BT Test, or the Biomarker Translation Test, is a CLIA compliant laboratory
test developed by Phoenix-based Provista Life Sciences. The test analyzes
blood for changes in multiple serum-based protein biomarkers levels that are
associated with the underlying pathology of breast cancer. The individual test
results, along with a brief patient-specific medical profile, are processed
through a proprietary data analysis procedure to generate a single numeric
value called the BT Score, which is indicative of the presence or absence of
breast cancer.

"The BT Test was designed to provide healthcare providers with another 'tool
in their toolbox' that can be used as a complement with current imaging
technologies in the fight to detect this devastating disease as early as
possible," said William J. Gartner, CEO and President of Provista. "For Dr.
Sweeten's patient, the BT Test played a role in detecting her breast cancer
and we are proud of that."

The BT Test is currently available in 41 states, 27 of which are considered
direct-to-consumer states where a physician's prescription is not required.
The BT Test can be ordered through a women's primary healthcare provider or
online. Once the sample is collected and tested, the results are sent to the
patient and/or their designated primary care physician. A complete list of
local Phoenix area providers is also available on the Provista Web site:
www.provistals.com. To find out more about the BT Test and how it can be
ordered visit their Web site or call 602-224-5500

About Provista Life Sciences
Provista Life Sciences is a biotechnology diagnostic development and
commercialization organization that provides the scientific and operating
management resources to rapidly advance the development and introduction of
novel diagnostic technologies into the domestic and global marketplace. For
more information, visit the company's Web site at www.ProvistaLS.com or call
602-224-5500

Dr. Keri Sweeten, M.D. - Understanding Women
Dr. Sweeten founded "Understanding Women" in 2003, a practice dedicated to
giving women a single place to receive their most sensitive and critical
healthcare needs in an understanding and caring environment. Dr. Sweeten is a
board-certified gynecologist, a Fellow of the American College of
Obstetricians and Gynecologists, Vice President of the Phoenix OB/Gyn Society,
a member of the Society of Laparoendoscopic Surgeons, the American Academy of
Cosmetic Surgeons, American Society of Lasers in Medicine and Surgery and the
American Urogynecologic Society. For more information, visit her website at
www.drsweeten.com or call 602-393-0661.

MEDIA CONTACTS:
The Lavidge Company
480.998.2600
Greg Sexton ext. 555
gsexton@lavidge.com
Anne Robertson ext. 537
arobertson@lavidge.com

SOURCE Provista

Greg Sexton, +1-480-998-2600, ext. 555, gsexton@lavidge.com, or Anne
Robertson, +1-480-998-2600, ext. 537, arobertson@lavidge.com, both of The
Lavidge Company, for Provista